500 Global is a multi-stage venture capital firm with $2.4 billion in assets under management. The firm invests in founders who are building fast-growing technology companies. It focuses on markets where technology, innovation, and capital can generate long-term value and economic growth. 500 Global collaborates with key stakeholders and provides advisory services to governments on fostering entrepreneurial ecosystems to support startups. The firm has invested in over 5,000 founders and more than 2,800 companies across 80+ countries. It has funded over 35 companies valued at more than $1 billion and over 160 companies valued at over $100 million, including those that are private, public, or have exited. The team consists of over 190 members based in more than 25 countries, with experience as entrepreneurs, investors, and operators from leading technology companies.

500 Global

Merck Capital Ventures invests in companies in various stages of development from the first round of institutional funding to later stage expansion opportunities. The firm does not invest in research based pharmaceutical, vaccine, and biotechnology companies. It seeks to invest in private Internet, commercialization, distribution and delivery of pharmaceuticals, and health care services. The firm typically invests in companies based in the United States and also considers non-United States companies with significant United States operations. It typically invests between $3 million and $8 million. The firm seeks to co-invest and prefers a board representation in its portfolio companies. It also seeks to provide follow-on financing. Merck Capital Ventures, LLC was founded in November 2000 and is based in Woodcliff Lake, New Jersey. Merck Capital Ventures, LLC operates as an investment arm of Merck & Co. Inc.

Merck Capital Ventures

(ERA) Entrepreneurs Roundtable Accelerator is New York City’s leading technology accelerator and early-stage venture capital fund. It has invested in 330+ start-ups since launching in 2011. Our alumni companies, who come from all over the world, are already playing leading roles in the evolution of virtually every major global industry. To date, ERA alumni companies have raised more than $2 billion in capital and collectively exceed $10 billion in market capitalization. ERA’s initial investment in participant companies is $150,000 on a post-money SAFE in return for 6% of each company. ERA runs two four-month sessions per year one each in the winter and summer. We invest $150,000 on a post-money SAFE in return for 6% of each company selected. In addition to this financial investment, our companies are immersed in our mentor-driven program. We also provide free office space, free hosting credits with several major cloud providers, and additional benefits through our legal, finance, accounting, and other business-service partners.

(ERA) Entrepreneurs Roundtable Accelerator

Alumni Ventures Group provides high-quality, diversified venture portfolios to individual investors who previously haven't had access to VC. It helps accredited alums from top entrepreneurial schools invest together in the ventures of fellow alums. The firm backs companies with an alumni connection and an institutional lead investor with expertise in the space. AVG also offers focused funds that allow any accredited investor access to a venture portfolio, diversified by type, sector, stage, and geography. Beth Obermiller, Michael Madden, and Mike Collins co-founded the firm in Manchester, New Hampshire in 2013.

Alumni Ventures

She's Well

She’s Well brings a Netflix-like subscription model to fertility, to help women, men, and couples to have children when they’re ready. The company works with its network of top-tier fertility centers to provide financing plans for fertility testing, IVF, egg freezing and sperm freezing. With an on-demand concierge care approach, She’s Well provides support and guidance, to make the fertility journey less confusing and isolating. 1 in 6 couples has trouble conceiving and we’re waiting longer to try. Women increasingly delay childbirth - one in three women in the U.S. has her first child after 30 and one in ten after 35. Male sperm count has decreased over 50 percent in the last decade. Despite all the solutions available on the market, infertility services remain available to only 1%. Health plans usually don't cover infertility treatments. The typical costs range from 12,000 to 20,000 dollars for IVF, plus another few thousand for the genetic testing involved to ensure the fetus is chromosomally normal. To help, She’s well started out offering subscription plans and concierge guidance to make fertility care more affordable and accessible to the 99%. We need to usher a world where decisions about family and career aren't ruled by biological clocks and where the best options, science, and care are available to everyone who wants to start a family.

She’s Well provides financial support for clients undergoing fertility treatments such as in vitro fertilization (IVF) and egg freezing procedures. The company offers monthly subscription plans priced between USD 99 to USD 149, for a period of five years for the said treatments, which can cost around USD 10,000-11,000 if incurred as a lump-sum expense.

Long-term demographic changes are finally bringing fertility technologies into focus.

Fertility Tech

She’s Well provides financial support for clients undergoing fertility treatments such as in vitro fertilization (IVF) and egg freezing procedures. The company offers monthly subscription plans priced between USD 99 to USD 149, for a period of five years for the said treatments, which can cost around USD 10,000-11,000 if incurred as a lump-sum expense.Patients have the choice of using their preferred fertility clinic or using one of the 250 clinics in the She’s Well network. In addition to funding support for the treatments, the company also supports patients through their digital concierge services.

<div>
 
 Glow offers apps that track data related to women’s fertility including ovulation cycle and pregnancy tracking. In addition to apps, the company also offers individualized fertility coaching, clinic identification and community support, and links patients with clinics for procedures such as egg freezing. 
 
 
 Glow generated around USD 0.3 million monthly revenue in October 2020, and as of February 2019 it had around 15 million users, and claims to have helped about 950,000 women get pregnant (from May 2013 to February 2019). In February 2019 Glow partnered with US Match Group (provider of dating products such as Match.com and Tinder), to provide Match’s employees with egg freezing benefits at reputed fertility clinics. In May 2017 it partnered with the National Institute of Health (NIH) to update a prediction model for couples trying to conceive.  
 
 
 In 2020, the company faced investigations into privacy and security failures involving its app. Glow agreed to pay a USD 0.25 million settlement in September 2020.
 
 
 
</div>

Glow

<div>
 
 Inne, based in Germany, offers an at-home mini lab kit for women. Hormone analysis is conducted based on saliva samples. The lab device connects to smartphones for storage and access to the analysis results.
 
 
 Unlike peer offerings, Inne does not attempt to predict future cycles and fertility dates, and instead educates users about their bodies, with information on what changes they should feel in response to the hormonal levels on the day.
 
 
 In May 2022, Inne 
 <a href="https://sp-edge.com/updates/10667?industryIds=40">
 raised USD 10 million
 </a>
 in an extension to its Series A round led by DSM Venturing. The company utilized the funds to continue the development of its mini lab and platform, grow its team, and support its expansion across the US, where it aims to enter with its perimenopause feature, followed by an expanded product launch in late 2022.
 
 
 
</div>

Inne

Proov (formerly known as MFB Fertility) offers the at-home “Proov'' ovulation and progesterone test. Proov tracks hormone levels in urine over multiple days, after suspected ovulation, and estimates whether the progesterone levels are sufficient for implantation, during the 7-10 day implantation window.As of May 2021, it was the only FDA-cleared urine PdG (urine metabolite of the progesterone hormone) test, and its method of determining the fertile window was patented. Moreover, it received the CE marking and expanded its sales footprint to Europe in June 2021.In June 2020, the company received a USD 1.3 million deal from the US Air Force, to provide Proov kits to enrolled individuals. The Proov test was distributed through leading US retailers such as Target and Amazon, and was also used by doctors across the country.Proov raised USD 9.7 million in Series A funding in December 2021, in a round led by Hambrecht Ducera Growth Ventures, with participation from other venture capital firms such as SteelSky Ventures, WCC Partners, and Lightship Capital, among others. The company expects to use the funding to grow its “Complete” product, which includes follicle-stimulating hormone tests and other multi-hormone tests that measure estrone glucuronide, LH and PdG.

Proov

<div>
 
 Progyny works with employers (primarily large enterprises in the US) to optimize the fertility benefits they offer for their employees. It connects employees to fertility specialists and clinics, and also offers extensive support to patients through their Progyny Patient Care Advocates, who provide clinical guidance, education, and emotional support.
 
 
 The company was founded as a fertility education platform and eventually included in vitro fertilization (IVF) referral network Fertility Authority and reproductive health company Auxogyn, into its network. The company pivoted into offering fertility benefit solutions in 2016, and launched Progyny Rx (fertility medication benefit) in 2018.
 
 
 Progyny connects patients to a network of 800 fertility specialists and nearly 600 clinic locations.&nbsp;
 
 
 Key customers and partnerships
 
 
 As of March 2022, the company served 264 enterprise customers (including Facebook, Microsoft, Google, and Nasdaq), and had 3.9 million active members.
 
 
 Funding and financials
 
 
 In October 2019, Progyny raised USD 130 million through its IPO, where it was listed on the Nasdaq.
 
 
 In FY2021, the company reported a revenue of USD 500.6 million reflecting a 45% YoY growth and a net income of USD 65.8 million. The company&rsquo;s revenue for 
 <a href="https://sp-edge.com/updates/14396">
 Q3 FY2022
 </a>
 amounted to USD 205.4 million, representing 68% YoY growth. The management&rsquo;s revenue guidance for FY2022 ranges between USD 775 million and USD 785 million, which implies an YoY growth of 55% to 57%.
 
</div>

Progyny

<div>
 
 Prima Temp offers the artificial intelligence (AI) assisted “Priya” intarvaginal ring sensor and accompanying app to continuously measure a woman’s core body temperature, predicting fertility windows. The app uses big data to improve its predictions, and the app notifies the user of fertile windows. The company also offers the “Kindara” fertility tracking app, which provides fertility related education and links users to a community of over 140,000 members.  
 
 
 The company raised USD 5 million in funding in May 2019 from Gedeon Richter, a Hungarian pharmaceutical company. Although the company primarily focuses on fertility monitoring, it intends to expand its offerings to include other areas of fertility management such as contraception and menopause.  
 
 
 
 
 
</div>

Prima Temp

Test kits which use saliva, blood, or temperature to determine hormone levels and form conclusions on fertility and fertility cycles.


Apps which use data science to identify fertility windows.

Organizations that freeze eggs or embryos for usage at a future date.


Services that analyze sperm samples (via test kit) and/or offer storage facilities for future use.

Companies specializing in supporting patient decision making, financing, clinical visits, physician referrals, and at-home treatments

Offers digital platforms and apps to provide fertility-related support

Uses AI/ML to improve cycle predictions and track symptoms

Some startups use genetic screening to tailor treatment or identify underlying issues

She's Well

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless